Purisys Eyes Importing Marijuana Extracts – Public Input Sought
Published Date: 3/13/2026
Notice
Summary
Purisys, LLC wants to become an official importer of certain controlled substances like marijuana and its extracts. People and companies involved can share their thoughts or ask for a hearing by April 13, 2026. This move could affect businesses handling these substances and might change how imports are managed, but no costs are mentioned yet.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Opium Imports for API Manufacturing
Purisys plans to import Opium, Raw (9600), Opium, Powdered (9639), and Opium, Granulated (9640) specifically to manufacture an Active Pharmaceutical Ingredient (API) only for distribution to its customers. The company states these imports are intended solely for API manufacture.
Bulk Manufacture Inputs: Phenylacetone & Poppy Straw
Purisys plans to import Phenylacetone (8501) and Poppy Straw Concentrate (9670) to bulk manufacture other controlled substances for distribution to its customers. The company explicitly states these imports are for bulk manufacture.
No Import of Finished Dosage Forms Allowed
The notice states that approval will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. Registrants must have business activity consistent with 21 U.S.C. 952(a)(2) to receive authorization.
Application to Import Many Controlled Drugs
Purisys, LLC filed an application on February 4, 2026 to be registered as an importer of a list of controlled substances (including Marihuana Extract 7350, Marihuana 7360, Tetrahydrocannabinols 7370, and multiple Schedule II drugs such as Methadone 9250 and Thebaine 9333). The notice lists each drug code and schedule and is open for comments or hearing requests through April 13, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2026-04969, Bulk Manufacturer of Controlled Substances Application: Stepan Company
Stepan Company wants to get official permission to make large amounts of cocaine and ecgonine, which are controlled substances. This affects other manufacturers and customers who use these drugs, and people have until May 12, 2026, to share their thoughts or ask for a hearing. No big money changes are mentioned, but this move could impact how these substances are made and sold.
Next: 2026-04971, Bulk Manufacturer of Controlled Substances Application: Pisgah Laboratories Inc
Pisgah Laboratories Inc wants to become a big-time maker of certain controlled drugs, including some strong medicines and research chemicals. People and companies affected can share their thoughts or ask for a hearing by May 12, 2026. This move could impact drug supply and regulation, but no costs or deadlines beyond the comment period are set yet.